Queensland researchers are attempting to create a vaccine in just 150 days to prove how far their response capabilities to a viral pandemic have come since Covid-19. The clock started on 10 February 2025 for The University of Queensland’s Vaccine Rapid Response Team, which has been tasked… Read More
Rwanda will start clinical trials of experimental vaccines and treatments for Marburg virus in the next few weeks, its health minister announced following news of an outbreak in the country. Marburg virus disease is highly virulent and causes haemorrhagic fever, with a fatality ratio of up… Read More
Scientists at the University of Oxford in the UK have launched a new clinical trial to test a vaccine to protect against “devastating” Marburg virus. This is the first-in-human trial of the ChAdOx1 Marburg vaccine, which has been developed and manufactured by researchers at the University… Read More
Danish biotech MinervaX has launched the first Phase I clinical study in older adults of its novel Group B Streptococcus (GBS) vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. GBS is a global unmet medical burden and can cause serious illness in people of all… Read More
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda’s vaccine candidate Qdenga for active immunisation against dengue infection from four years of age. Dengue is the fastest spreading mosquito-borne virus and was recognised by the World Health Organization (WHO) in 2019… Read More
A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease. The new vaccine, VSV-SUDV, completely… Read More
An experimental vaccine against Marburg virus (MARV) was proved to be safe and induced an immune response in a small, first-in-human clinical trial. In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of… Read More
New research from the International Longevity Centre (ILC) in London, UK, finds that social media advertising can be a cost-effective way of engaging older people in deprived communities with vaccination. The approach In the past, researchers found that older people are less likely to use… Read More
Levels of antibodies in the blood of vaccinated people that can recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National… Read More
Novavax has announced its participation in a newly expanded investigator-initiated Phase II clinical trial called Comparing Covid-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. Novavax’ recombinant protein vaccine candidate, NVX-CoV2373, is one of four Covid-19… Read More
RSV is a complicated virus, and traditional vaccine methods have not worked. But UW’s Institute for Protein Design may have solved the problem using computational design. With the help of an innovative computer program, Icosavax has constructed virus-like particles (VLPs) using a two-part assembly (like a soccer ball). Adam Simpson,… Read More
